From the Department of Pathology and Laboratory Medicine, Cooper Medical School of Rowan University, Camden, New Jersey.
Arch Pathol Lab Med. 2019 Jun;143(6):677-682. doi: 10.5858/arpa.2017-0260-OA. Epub 2018 Apr 24.
CONTEXT.—: Evaluation of fluid specimens involved by serous carcinoma might potentially include PAX8, GATA3, Uroplakin II, SOX2, and SALL4 antibodies. Those markers are commonly employed for diagnosing carcinomas of various types, including urothelial malignancies and germ cell tumors. There have been no comprehensive immunohistochemical studies, to our knowledge, for those markers on fluid specimens involved by serous carcinoma.
OBJECTIVE.—: To evaluate immunohistochemical markers PAX8, GATA3, SOX2, uroplakin II, and SALL4 in the diagnosis of high-grade serous carcinoma in fluid specimens.
DESIGN.—: We examined 113 fluids (96 ascites specimens and 17 pleural fluid specimens) that were positive for carcinoma. Most (94 cases; 83.2%) consisted of high-grade serous carcinoma of Müllerian origin. Nineteen cases of non-high-grade serous carcinoma (including one case of low-grade serous carcinoma) of gynecologic origin were also included as anecdotal data.
RESULTS.—: In 113 fluid specimens with positive results for carcinoma, including nonserous types, 99 (87.6%) had positive results for PAX8, 19 (16.8%) for GATA3; 19 (16.8%) for SOX2, 23 (20.4%) for uroplakin II, and 8 (7.1%) for SALL4. Of 94 fluids (83.2%) involved with high-grade serous carcinoma, 84 (89.4%) had positive results for PAX8, 18 (19.1%) for GATA3, 17 (18.1%) for SOX2, 22 (23.4%) for uroplakin II, and 8 (8.5%) for SALL4. Some of these specimens showed reactivity for more than one immunohistochemical marker.
CONCLUSIONS.—: Most fluids involving high-grade serous carcinoma showed positive results for PAX8, and some cases expressed GATA3, SOX2, uroplakin II, and SALL4. Serous carcinoma in fluids may be positive for immunohistochemical markers not thought of traditionally as associated with gynecologic malignancy, an important consideration in avoiding misdiagnosis.
在涉及浆液性癌的液体标本的评估中，可能包括 PAX8、GATA3、Uroplakin II、SOX2 和 SALL4 抗体。这些标志物常用于诊断各种类型的癌，包括尿路上皮恶性肿瘤和生殖细胞肿瘤。据我们所知，尚无关于这些标志物在涉及浆液性癌的液体标本中的全面免疫组织化学研究。
评估 PAX8、GATA3、SOX2、uroplakin II 和 SALL4 免疫组织化学标志物在液体标本中高级别浆液性癌的诊断中的作用。
我们检查了 113 份液体标本（96 份腹水标本和 17 份胸腔液标本），这些标本均为癌阳性。大多数（94 例；83.2%）由源自 Müllerian 的高级别浆液性癌组成。还包括 19 例源自妇科的非高级别浆液性癌（包括 1 例低级别浆液性癌）作为偶然数据。
在包括非浆液性类型的 113 份阳性结果为癌的液体标本中，99 份（87.6%）PAX8 阳性，19 份（16.8%）GATA3 阳性；19 份（16.8%）SOX2 阳性，23 份（20.4%）uroplakin II 阳性，8 份（7.1%）SALL4 阳性。在 94 份（83.2%）涉及高级别浆液性癌的液体中，84 份（89.4%）PAX8 阳性，18 份（19.1%）GATA3 阳性，17 份（18.1%）SOX2 阳性，22 份（23.4%）uroplakin II 阳性，8 份（8.5%）SALL4 阳性。其中一些标本对不止一种免疫组织化学标志物呈反应。
大多数涉及高级别浆液性癌的液体标本 PAX8 阳性，一些病例表达 GATA3、SOX2、uroplakin II 和 SALL4。在液体中发现的浆液性癌可能对免疫组织化学标志物呈阳性，而这些标志物传统上不被认为与妇科恶性肿瘤有关，这是避免误诊的一个重要考虑因素。
Zotero 插件